When Alfred Williams was admitted to Ochsner Medical Center in December, the 41-year-old father of five had exhausted all treatment options for his enlarged heart. His condition, known as dilated cardiomyopathy, had progressed to end-stage heart failure affecting both sides of his heart. Unable to walk, he had been confined to a bed for months. Hospice care seemed like the only option Mr. Williams had left… until doctors approached him about becoming Ochsner's first patient to receive the SynCardia temporary Total Artificial Heart.
[More]
Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.
[More]
Researchers discovered that small pieces of genetic material called microRNAs link the two defining characteristics of fit muscles: the ability to burn sugar and fat and the ability to switch between slow- and fast-twitch muscle fibers.
[More]
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced that the Food and Drug Administration granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator series.
[More]
The National Transitions of Care Coalition has cited patient education as a required component of post hospital health management and disease prevention framework. Today's technologies and digital delivery options allows health providers to target reductions in re-admissions, and emergency department visits, while improving patient compliance and patient safety within the hospital.
[More]
A study appearing in the Journal of Nutritional Biochemistry- demonstrates that grapes are able to reduce heart failure associated with chronic high blood pressure (hypertension) by increasing the activity of several genes responsible for antioxidant defense in the heart tissue.
[More]
Patients with increasing accumulations of coronary artery calcium were more than six times more likely to suffer from a heart attack or die from heart disease than patients who didn't have increasing accumulations, according to a recent study published in the Journal of the American College of Cardiology.
[More]
Adolescents and young adults (ages 15-39) make up 5 and 6 percent of all breast cancer cases in the United States and have the lowest five-year survival rates.
[More]
Use of biventricular rather than conventional right ventricular pacing results in better clinical outcomes in patients who have heart failure with atrioventricular block and left ventricular systolic dysfunction, show the results of BLOCK HF.
[More]
CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients.
[More]
The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. The congress takes place 25-28 May at the Centro de Congressos de Lisboa in Lisbon, Portugal.
[More]
Prospective students, lifelong learners, or anyone simply interested in patient safety can get a thorough overview of the topic and a taste of the Johns Hopkins educational experience beginning June 3.
[More]
Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy.
[More]
Using a one-of-a-kind computer-aided program, Mayo Clinic has developed and implemented a Mayo-wide electronic warning system to identify patients at risk of QT-related deaths from an abnormality in the heart's electrical system.
[More]
Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic acid) and activating peroxisome proliferator-activator receptorγ (PPARγ) with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome.
[More]
ImaCor Inc., the developer of the world's only hemodynamic transesophageal echocardiography management device, announced today that transplant and mechanical circulatory support physicians from around the world gathered in Montreal at an hTEE symposium to hear from heart failure experts about the value of hTEE management.
[More]
Omega-3 polyunsaturated fatty acids, namely DHA and EPA found in fatty fish, are associated with lower risk of heart failure mortality in adults with chronic heart failure or who have experienced a heart attack.
[More]
By 2030, you - and every U.S. taxpayer - could be paying $244 a year to care for heart failure patients, according to an American Heart Association policy statement.
[More]
Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.
[More]
Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.
[More]